Algorae Pharmaceuticals Ltd (ASX: 1AI), headquartered in Melbourne, has reported a significant technical milestone with the independent preclinical validation of its AI-driven drug-combination platform, AlgoraeOS v1 (AOS1). The validation, completed at the Victorian Centre for Functional Genomics (VCFG) at the Peter MacCallum Cancer Centre, provides the first external confirmation that AOS1 can identify synergistic drug pairs with real biological impact.

Algorae Pharmaceuticals Ltd (ASX: 1AI) has executed a binding term sheet with Cadila Pharmaceuticals Limited for a proposed license and supply agreement covering Australia and New Zealand. The partnership would see Algorae launch two generic medicines targeting cardiovascular and metabolic disorders, with next steps focused on finalising a definitive agreement and preparing for TGA registration.

Algorae Pharmaceuticals Ltd (ASX: 1AI) has taken a major step toward establishing a commercial presence in the Australian and New Zealand markets. The company has entered into an exclusive licensing agreement with global pharmaceutical manufacturer Sakar Healthcare Limited (NSE: SAKAR, BSE: 538377) (Figure 1) to launch five oncology medicines across the region.